Form: PREM14A

Preliminary proxy statement relating to a merger, acquisition, or disposition

April 13, 2023

Documents

Exhibit 107

 

Calculation of Filing Fee Tables

 

Schedule 14A

(Form Type)

 

Enzo Biochem, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Transaction Valuation

 

    Proposed
Maximum
Aggregate
Value of
Transaction (1)(2)		     Fee rate     Amount of
Filing Fee		  
Fees to Be Paid   $ 146,000,000 (3)     0.00011020     $ 16,089.20  
Fees Previously Paid   $ 0             $ 0  
Total Transaction Valuation   $ 146,000,000                  
Total Fees Due For Filing                   $ 16,089.20  
Total Fees Previously Paid                   $ 0  
Total Fee Offsets                   $ 0  
Net Fee Due                   $ 16,089.20  

 

(1) Title of each class of securities to which transaction applies: N/A

 

(2) The aggregate number of securities to which the asset sale applies: N/A

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

The filing fee was determined by multiplying 0.00011020 by $146,000,000. The purchase price payable under the Asset Purchase Agreement (as defined in the proxy statement) is $146,000,000 to be received by Enzo Biochem, Inc.